News | Heart Failure | May 12, 2017

Leadless Endocardial CRT Pacing Effective for Heart Failure Patients

Long-term results show first wireless CRT device proven to be a safe alternative to traditional pacing systems for heart failure patient populations

WiSE CRT System is a wireless cardiac resynchonization therapy device with no lead wires

The WiSE CRT System uses a tiny implant in the left ventricle to synchronize the heart, overcoming limitations of traditional Cardiac Resynchronization Therapy (CRT) in heart failure patients.

May 12, 2017 – New study proves safety of novel, wireless pacing system, WiSE CRT (Wireless Stimulation Endocardially for cardiac resynchronization therapy) two years after implantation. The study is the first to report on the medium-long term feasibility of the EBR WiSE cardiac resynchronization therapy (CRT) leadless pacing system for heart failure patients and was presented at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual Scientific Sessions. 

The WiSE-CRT is currently the only wireless, endocardial (inside the heart) pacing system for stimulating the heart’s left ventricle (LV). The implant is roughly the size of a large grain of rice and uses ultrasound technology to transfer energy from a subcutaneous pulse generator to a receiver-electrode implanted on the LV endocardial wall.

Watch the VIDEO “How to Implant a Leadless CRT LV Pacing System.”

The multicenter study was conducted in various locations across Europe including the United Kingdom, Germany, Czech Republic and Denmark. Researchers enrolled a total of 33 patients that underwent implantation. Prior to the study, all patients experienced progressive heart failure with no response to conventional CRT treatment therapy.

LV capture was possible in all cases throughout the study. The average mega joule (mJ) required for electrical capture was 0.38, 0.36, 0.33, 0.37, 0.19 and 0.25 at one week, one, two and six months, and at one and two years, respectively. The two-year threshold trend was found to be similar to those for conventional pacing system. 

“The results are very encouraging because it’s the first time we are seeing the long-term outcome of this wireless pacing system and was demonstrated to be safe and feasible for heart failure devices,” said lead author, Simon James, MRCP, electrophysiologist, James Cook University Hospital in Middlesbrough, United Kingdom. “By eliminating the challenges that come with leads seen in a conventional pacing system, this novel device provides a new treatment alternative that has the potential to improve the patient’s overall quality of life.”

Study authors note that there is interest to further test the long-term efficacy with WiSE-CRT and review the results on a larger number of patients. There is currently a clinical trial taking place to test the safety and effectiveness of the device specifically in the United States.

Read about the U.S. trial in the article “FDA Approves U.S. Study of EBR Systems' Wireless Cardiac Pacing System.”

Approximately 26 million people worldwide are living with heart failure.[1] Successful CRT therapy can help reduce heart failure symptoms, hospitalizations, and mortality by synchronizing the left and right ventricles. Although traditional CRT systems are widely used in patients, approximately 30 percent of patients – and as high as 40 percent to 50 percent in some studies – do not respond to this conventional therapy.[2] There are leads in conventional CRT systems and that can increase the risk of infection due to a physical connection from the heart to externalized (outside the blood stream) components and the restricted choice of electrode site can result in failure for patients to benefit.

For more information: www.HRSonline.org, www.hrssessions.org

References:

1. Ponikowski, Piotr, Stefan D. Anker, Khalid F. AlHabib, Martin R. Cowie, Thomas Force, Shengshou Hu, Tiny Jaarsma, Henry Krum, Vishal Rastogi, Luis E. Rohde, Umesh C. Samal, Hiroaki Shimokawa, Bambang Budi Siswanto, Karen Silwa, and Gerasimon Filippatos." Heart Failure: Preventing Disease and Death Worldwide." (n.d.): n. pag. 15 May 2014. Web.

2. Leeor M. Jaffe and Daniel P. Morin. "Cardiac Resynchronization Therapy: History, Present Status, and Future Directions." The Ochsner Journal (2014): 596-607. Web.

3.  Simon James, Darragh J. Twomey, Christian Butter, Sam Riahi, and Andrew Turley. Heart Rhythm 2017 meeting session, “Contemporary Considerations in CRT: Left Ventricular Endocardial Pacing with a Novel Wireless CRT System (WiSE-CRT): Pacing Threshold Trends: Medium Term 2-Year Data.” Presented May 12, 2017.

Related Content

CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Overlay Init